{"id":"faster-acting-insulin-aspart","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201496","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin aspart is a recombinant human insulin analog with a single amino acid substitution (proline to aspartic acid at position 28 of the B chain) that reduces self-association and accelerates absorption from subcutaneous injection sites compared to regular human insulin. The faster-acting formulation achieves peak serum levels more rapidly, allowing for improved postprandial glucose control when dosed immediately before or during meals in patients with diabetes.","oneSentence":"Faster-acting insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:12.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04149262","phase":"","title":"Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-15","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT04698018","phase":"PHASE1","title":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT04381429","phase":"PHASE4","title":"Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-08-17","conditions":"Cystic Fibrosis-related Diabetes","enrollment":38},{"nctId":"NCT03987802","phase":"","title":"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-01-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT03659799","phase":"PHASE4","title":"Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-04-12","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT03770767","phase":"PHASE3","title":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Pregnancy Complications","enrollment":216},{"nctId":"NCT04759144","phase":"NA","title":"FASter Insulin in Closed-loop Technology in Children","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2021-03-12","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT04655690","phase":"PHASE1","title":"A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-09","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT03579615","phase":"NA","title":"Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2020-12-23","conditions":"Diabetes Mellitus, Type 1","enrollment":18},{"nctId":"NCT03268005","phase":"PHASE3","title":"Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"/\"NovoLog\" in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-09-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1264},{"nctId":"NCT04853030","phase":"NA","title":"Fast Advanced Closed-Loop Therapy","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2021-04-06","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT04772729","phase":"PHASE4","title":"Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2021-03-01","conditions":"Diabetes type1, Diabetes Mellitus, Type 1","enrollment":77},{"nctId":"NCT04233203","phase":"","title":"Faster Aspart on Insulin-pump Treated T1DM Patients","status":"COMPLETED","sponsor":"Jesús Moreno Fernández","startDate":"2020-01-31","conditions":"Type 1 Diabetes","enrollment":48},{"nctId":"NCT04711382","phase":"","title":"The Use of Faster Acting Aspart in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2018-01-29","conditions":"Type 1 Diabetes, Insulin, Time in Range","enrollment":438},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03977727","phase":"PHASE3","title":"FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump","status":"COMPLETED","sponsor":"Texas Diabetes & Endocrinology, P.A.","startDate":"2019-06-11","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT04055480","phase":"NA","title":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2019-08-10","conditions":"Type 1 Diabetes","enrollment":25},{"nctId":"NCT03723759","phase":"PHASE1","title":"A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-26","conditions":"Diabetes Mellitus, Type 1","enrollment":56},{"nctId":"NCT02825251","phase":"PHASE3","title":"Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-07-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":472},{"nctId":"NCT03565666","phase":"PHASE2, PHASE3","title":"The Insulin-Only Bionic Pancreas Bridging Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-07-09","conditions":"Type1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT03407599","phase":"PHASE1","title":"A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":46},{"nctId":"NCT02500706","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":1108},{"nctId":"NCT01831765","phase":"PHASE3","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08-26","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":1290},{"nctId":"NCT01850615","phase":"PHASE3","title":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":323},{"nctId":"NCT02670915","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":834},{"nctId":"NCT02933853","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-10-14","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":61},{"nctId":"NCT03215498","phase":"PHASE1","title":"A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-07-03","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":58},{"nctId":"NCT01819129","phase":"PHASE3","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":881},{"nctId":"NCT01618188","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":52},{"nctId":"NCT01934712","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08-30","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT02003677","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11-29","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT02568280","phase":"PHASE1","title":"Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":42},{"nctId":"NCT01774565","phase":"NA","title":"Closed-loop Insulin Delivery in the General Ward","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2016-08","conditions":"Diabetes Mellitus","enrollment":43},{"nctId":"NCT03335501","phase":"PHASE2","title":"Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-04-01","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03212950","phase":"NA","title":"Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2017-07-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01999322","phase":"PHASE3","title":"A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11-19","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":37},{"nctId":"NCT02035371","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-13","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":41},{"nctId":"NCT02089451","phase":"PHASE1","title":"A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-03-17","conditions":"Diabetes, Healthy","enrollment":21},{"nctId":"NCT01121276","phase":"PHASE1","title":"A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-04","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":82},{"nctId":"NCT02033239","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":46},{"nctId":"NCT02131246","phase":"PHASE1","title":"A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT01924637","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":36},{"nctId":"NCT01682902","phase":"PHASE1","title":"A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":43},{"nctId":"NCT01992588","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT01469143","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":40},{"nctId":"NCT01296438","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-02","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NN1218"],"phase":"phase_3","status":"active","brandName":"Faster-acting insulin aspart","genericName":"Faster-acting insulin aspart","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Faster-acting insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":17,"withResults":8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}